Further investigation into the synergistic relationship between IFN-γ and IL-6 may provide insight into how these ITGB4-targeted immunotherapies function in vivo, and potentially provide additional effort to improve cancer therapeutic efficacy. This evidence concerns the gene IFNG and cancer.